4basebio (LON:4BB) Price Target Lowered to GBX 1,400 at Royal Bank Of Canada

4basebio (LON:4BB) had its target price decreased by investment analysts at Royal Bank Of Canada from GBX 1,600 to GBX 1,400 in a note issued to investors on Monday,Digital Look reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 180.00% from the stock’s current price.

4basebio Trading Down 4.8%

Shares of LON 4BB traded down GBX 25 during midday trading on Monday, hitting GBX 500. The company’s stock had a trading volume of 1,239 shares, compared to its average volume of 1,727. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The business’s 50 day moving average is GBX 502.12 and its two-hundred day moving average is GBX 554.32. 4basebio has a 12-month low of GBX 420 and a 12-month high of GBX 1,040. The firm has a market cap of £77.43 million, a P/E ratio of -4.59 and a beta of 1.09.

4basebio (LON:4BB) last announced its quarterly earnings data on Wednesday, May 20th. The company reported GBX (1.09) earnings per share (EPS) for the quarter. The company had revenue of GBX 169 million during the quarter. As a group, equities research analysts expect that 4basebio will post -3.43 EPS for the current year.

Insider Transactions at 4basebio

In other news, insider Amy Walker acquired 1,863 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of GBX 509 per share, with a total value of £9,482.67. 12.09% of the stock is currently owned by company insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.